- Home
- INTC vs ABBV Comparison
INTC vs ABBV Comparison
Compare INTC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTC | ABBV |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.8B | 451.5B |
| IPO Year | 2007 | 2012 |
Fundamental Metrics
Financial Performance| Metric | INTC | ABBV |
|---|---|---|
| Price | $101.68 | $262.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 34 | 18 |
| Target Price | $63.38 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 77.0M | 2.7M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 98.63 | N/A |
| EPS | N/A | ★ 2.42 |
| Revenue | $52,853,000,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $4.59 | $11.87 |
| Revenue Next Year | $7.73 | $8.12 |
| P/E Ratio | ★ N/A | $108.30 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $24.45 | $190.75 |
| 52 Week High | $142.35 | $267.47 |
Technical Indicators
Market Signals| Indicator | INTC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 58.14 |
| Support Level | $83.43 | $242.14 |
| Resistance Level | $107.57 | $264.26 |
| Average True Range (ATR) | 3.98 | 5.28 |
| MACD | 1.15 | -0.07 |
| Stochastic Oscillator | 55.08 | 89.06 |
Price Performance
Historical ComparisonAbout INTC Intel Corporation
Intel is a leading digital chipmaker focused on designing and manufacturing microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and led the semiconductor industry down the path of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. The company is seeking to reinvigorate its chip manufacturing business, Intel Foundry, while developing leading-edge products in its Intel Products business segment.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.